One can only dream of such vaccination numbers in Germany. According to official information, 243 million people have been vaccinated in the People’s Republic of China. With a population of 1.4 billion, it constitutes a good 14 percent of the total population. For comparison: Germany currently has eight percent who have been fully vaccinated. China has essentially developed five vaccines for the fight against Kovid-19. The two most popular come from Beijing state-owned company Sinoparm and private company Sinovac. The special thing about these vaccines: they use inactivated viruses and are therefore less effective.
However, Chinese vaccines are already approved in more than 45 countries. They are currently used exclusively in countries in the global south; Ultimately, the requirement is very good worldwide, and means against Kovid-19 are still scarce. The WHO is now also considering approving cyanopharma and synovac vaccines for emergency use. In the context of the COVID-19 Vaccines Global Access (COVAX) initiative, particularly low-income countries should be given an effective way to protect their populations.
Weak data
However, the problem is that there is hardly any reliable data on Chinese vaccines worldwide, which is partly due to the fact that China itself does not have enough infected people to conduct meaningful studies. The WHO approval process is therefore long before the Chinese could produce such data on vaccines. And yet the expectations are already very large. British trade magazine Nature In this context, an epidemiologist at the University of Santiago, who is completely dependent on WHO’s support for Synovac and Sinopharm’s products: WHO’s support is very important, the Chilean doctor said. A positive response would be “very good news for vaccine developers and for countries interested in acquiring these vaccines.”
The WHO may decide approval early next week. It would be a bombardment for China, after all, the country wants to produce between three and five billion by the end of 2021.
Read full article Here.
